Pharmacokinetics and Safety of Tiagabine in Subjects with Various Degrees of Hepatic Function

Abstract

Because of the decreased drug elimination caused by liver function impairment, reduced doses or increased dosing interval or both may be needed to attain therapeutic plasma drug concentrations. Time to reach steady state also may be prolonged. The patients should be monitored closely for potential neurologic adverse events.